Amersfoort, July 4 – Nutreco announces today that it has invested in Israeli startup ViAqua as part of its focus on combatting disease in the aquaculture industry.
ViAqua is developing the first orally-administered treatment for shrimp that improves resistance to viral diseases, including White Spot Syndrome Virus (WSSV), and prevents viral epidemics. Nutreco has taken a meaningful minority share that will conditionally grow over time.
The solution offered by ViAqua, which was founded in 2014, uses a proprietary particle to disable viral infections. In the future, ViAqua intends to expand to include more species, like other shellfish such as lobster and crab, and small fish.